Quality of life of ovarian cancer patients treated with combined platinum taxane chemotherapy: a systematic review of the literature

[1] Bezjak A(2004)Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study J Clin Oncol 22 4595-4603

[2] Tu D(2016)Effect of chemotherapy on health-related quality of life among early-stage ovarian cancer survivors: a study from the population-based PROFILES registry Curr Oncol 23 e556-e562

[3] Bacon M(2020)Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial Lancet Oncol 21 969-977

[4] Osoba D(2016)Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life Support Care Cancer 24 1241-1249

[5] Zee B(2003)Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study Gynecol Oncol 88 9-16

[6] Stuart G(2011)Health-related quality of life in ovarian cancer patients and its impact on clinical management Expert Rev Pharmacoecon Outcomes Res 11 421-431

[7] Roy JA(2012)Beliefs and perceptions of women with newly diagnosed breast cancer who refused conventional treatment in favor of alternative therapies Oncologist 17 607-612

[8] Piccart M(2010)Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer J Clin Oncol 28 4162-4169

[9] Eisenhauer E(2016)Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome Eur J Cancer 59 22-33

[10] Bhugwandass CS(1983)Systematic understanding of cancer patients who refuse treatment Psychother Psychosom 39 180-189

[1] Bezjak A(2004)Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study J Clin Oncol 22 4595-4603

[2] Tu D(2016)Effect of chemotherapy on health-related quality of life among early-stage ovarian cancer survivors: a study from the population-based PROFILES registry Curr Oncol 23 e556-e562

[3] Bacon M(2020)Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial Lancet Oncol 21 969-977

[4] Osoba D(2016)Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life Support Care Cancer 24 1241-1249

[5] Zee B(2003)Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study Gynecol Oncol 88 9-16

[6] Stuart G(2011)Health-related quality of life in ovarian cancer patients and its impact on clinical management Expert Rev Pharmacoecon Outcomes Res 11 421-431

[7] Roy JA(2012)Beliefs and perceptions of women with newly diagnosed breast cancer who refused conventional treatment in favor of alternative therapies Oncologist 17 607-612

[8] Piccart M(2010)Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer J Clin Oncol 28 4162-4169

[9] Eisenhauer E(2016)Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome Eur J Cancer 59 22-33

[10] Bhugwandass CS(1983)Systematic understanding of cancer patients who refuse treatment Psychother Psychosom 39 180-189